Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

MGNX – Macrogenics Inc

MGNX — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

8.12

Margin Of Safety %

Put/Call OI Ratio

0.13

EPS Next Q Diff

0.27

EPS Last/This Y

1.21

EPS This/Next Y

-1.45

Price

3.95

Target Price

6.75

Analyst Recom

2.29

Performance Q

32

Upside

-464.4%

Beta

1.2

Ticker: MGNX




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-05-18MGNX4.340.080.095534
2026-05-19MGNX4.510.080.685558
2026-05-20MGNX4.470.090.215616
2026-05-21MGNX4.240.100.175658
2026-05-22MGNX4.520.100.095669
2026-05-26MGNX4.470.106.006011
2026-05-27MGNX4.380.100.656035
2026-05-28MGNX4.220.100.146034
2026-05-29MGNX4.180.1018.186043
2026-06-02MGNX4.050.147.146241
2026-06-03MGNX4.210.122.366150
2026-06-04MGNX4.260.150.006284
2026-06-05MGNX3.90.151.196286
2026-06-08MGNX3.880.150.366319
2026-06-09MGNX3.920.150.026324
2026-06-10MGNX3.860.130.027301
2026-06-11MGNX4.010.130.007301
2026-06-12MGNX3.950.130.007311
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-05-18MGNX4.3415.8- -1.76
2026-05-19MGNX4.5115.8- -1.76
2026-05-20MGNX4.4843.9- -2.13
2026-05-21MGNX4.2443.9- -2.13
2026-05-22MGNX4.51145.2- 0.04
2026-05-26MGNX4.47145.2- 0.04
2026-05-27MGNX4.38145.2- 0.04
2026-05-28MGNX4.21145.2- 0.04
2026-05-29MGNX4.18145.2- 0.04
2026-06-01MGNX4.16145.2- 0.04
2026-06-02MGNX4.05145.2- 0.04
2026-06-03MGNX4.21145.2- 0.04
2026-06-04MGNX4.26145.2- 0.04
2026-06-05MGNX3.91145.2- 0.04
2026-06-08MGNX3.88145.2- 0.04
2026-06-09MGNX3.92145.2- 0.04
2026-06-10MGNX3.87145.2- 0.04
2026-06-11MGNX4.01145.2- 0.04
2026-06-12MGNX3.95145.2- 0.04
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-05-18MGNX0.00-14.624.77
2026-05-19MGNX0.00-14.624.77
2026-05-20MGNX0.00-14.624.77
2026-05-21MGNX0.00-14.624.77
2026-05-22MGNX0.00-14.624.77
2026-05-26MGNX0.005.264.78
2026-05-27MGNX0.005.264.78
2026-05-28MGNX0.005.267.95
2026-05-29MGNX0.005.267.95
2026-06-02MGNX0.004.607.95
2026-06-03MGNX0.004.607.95
2026-06-04MGNX0.004.607.95
2026-06-05MGNX0.004.607.95
2026-06-08MGNX0.004.487.95
2026-06-09MGNX0.004.487.95
2026-06-10MGNX0.004.488.12
2026-06-11MGNX0.004.488.12
2026-06-12MGNX0.004.488.12
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.58

Avg. EPS Est. Current Quarter

0.26

Avg. EPS Est. Next Quarter

-0.31

Insider Transactions

Institutional Transactions

4.48

Beta

1.2

Average Sales Estimate Current Quarter

59

Average Sales Estimate Next Quarter

32

Fair Value

Quality Score

34

Growth Score

27

Sentiment Score

80

Actual DrawDown %

86.5

Max Drawdown 5-Year %

-96.3

Target Price

6.75

P/E

Forward P/E

PEG

P/S

1.6

P/B

11.87

P/Free Cash Flow

EPS

-1.11

Average EPS Est. Cur. Y​

0.04

EPS Next Y. (Est.)

-1.41

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-44.79

Relative Volume

0.51

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

1.8

EPS 1 30Days Diff

1.76

EBIT Estimation

MGNX Healthcare
$3.96
📉
Swing / Pullback
Buy the dip on strong trends
58 /100
WATCH
Trend
14/20
Pullback
11/25
Volume
11/15
Valuation
9/20
TP/AR
5/10
Options
8/10
RSI
51.6
Range 1M
51.8%
Sup Dist
2.8%
🚀
Momentum Growth
Ride accelerating trends
N/A
35 /100
WEAK
Momentum
8/25
Growth
9/30
Estimates
4/20
Inst/Vol
8/15
Options
6/10
EPS Yr
-4.2%
EPS NY
-24.3%
52W%
81%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +70.5% upside
Quality
6/30
Valuation
14/30
Growth
7/25
Stability
4/10
LT Trend
4/5
Upside
+70.5%
Quality
34
MacroGenics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 293
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
MGNX

Latest News

Caricamento notizie per MGNX
stock quote shares MGNX – Macrogenics Inc Stock Price stock today
news today MGNX – Macrogenics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MGNX – Macrogenics Inc yahoo finance google finance
stock history MGNX – Macrogenics Inc invest stock market
stock prices MGNX premarket after hours
ticker MGNX fair value insiders trading